

Joel S Perlmutter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8743158/publications.pdf>

Version: 2024-02-01

154
papers

7,161
citations

116194

36
h-index

78623

77
g-index

163
all docs

163
docs citations

163
times ranked

12870
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiosynthesis and evaluation of a fluorine-18 radiotracer [¹⁸ F]FS1P1 for imaging sphingosine-1-phosphate receptor 1. <i>Organic and Biomolecular Chemistry</i> , 2022, 20, 1041-1052.	1.5	5
2	Quantifying regional α -synuclein, amyloid β , and tau accumulation in lewy body dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 106-121.	1.7	21
3	Head tremor in cervical dystonia: Quantifying severity with computer vision. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120154.	0.3	6
4	Hold that pose: capturing cervical dystonia's head deviation severity from video. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 684-694.	1.7	9
5	Ethical Challenges in the Commercialization of Neurotechnology: Contending with Competing Priorities. <i>AJOB Neuroscience</i> , 2022, 13, 60-62.	0.6	1
6	Biodistribution of Biomimetic Drug Carriers, Mononuclear Cells, and Extracellular Vesicles, in Nonhuman Primates. <i>Advanced Biology</i> , 2022, 6, e2101293.	1.4	7
7	Radiosynthesis and characterization of a carbon-11 PET tracer for receptor-interacting protein kinase 1. <i>Nuclear Medicine and Biology</i> , 2022, 110-111, 18-27.	0.3	1
8	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. <i>Neurology</i> , 2022, 99, .	1.5	8
9	A tissue α fraction estimation α -based segmentation method for quantitative dopamine transporter SPECT. <i>Medical Physics</i> , 2022, 49, 5121-5137.	1.6	5
10	Presymptomatic Testing and Confidentiality in the Age of the Electronic Medical Record. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 80-83.	0.9	2
11	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. <i>Movement Disorders</i> , 2021, 36, 948-954.	2.2	26
12	Resting α State Functional Connectivity Predicts α STN DBS α Clinical Response. <i>Movement Disorders</i> , 2021, 36, 662-671.	2.2	28
13	Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021, 268, 1945-1950.	1.8	12
14	Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 21.	1.1	3
15	Quality of life in isolated dystonia: non-motor manifestations matter. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 622-628.	0.9	27
16	Excellent Outcome of Acute Necrotizing Encephalopathy in an Adult With Bacterial Infections, Case Report. <i>Neurohospitalist, The</i> , 2021, 11, 351-355.	0.3	2
17	Spatially constrained kinetic modeling with dual reference tissues improves ¹⁸ F-flortaucipir PET in studies of Alzheimer disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3172-3186.	3.3	6
18	Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers. <i>Toxicological Sciences</i> , 2021, 182, 132-141.	1.4	3

#	ARTICLE	IF	CITATIONS
19	The Dystonia Coalition: A Multicenter Network for Clinical and Translational Studies. <i>Frontiers in Neurology</i> , 2021, 12, 660909.	1.1	16
20	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. <i>Nature Genetics</i> , 2021, 53, 787-793.	9.4	82
21	FDA's green light, science's red light. <i>Science</i> , 2021, 372, 1371-1371.	6.0	6
22	Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2559-2568.	2.2	13
23	A Multi-center Genome-wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021, 36, 2795-2801.	2.2	5
24	Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks. <i>Neurology</i> , 2021, 97, 545-547.	1.5	25
25	Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. <i>Brain and Behavior</i> , 2021, 11, e2292.	1.0	11
26	Distinct progression patterns across Parkinson disease clinical subtypes. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1695-1708.	1.7	4
27	Aducanumab: look before leaping. <i>Nature Medicine</i> , 2021, 27, 1499-1499.	15.2	10
28	Revisiting FDA Approval of Aducanumab. <i>New England Journal of Medicine</i> , 2021, 385, 769-771.	13.9	104
29	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	1.7	2
30	Oromandibular Dystonia: A Clinical Examination of 2,020 Cases. <i>Frontiers in Neurology</i> , 2021, 12, 700714.	1.1	20
31	Moving the U.S. Food and Drug Administration Forward. <i>Annals of Internal Medicine</i> , 2021, 174, 1626-1627.	2.0	5
32	<i>In Vitro</i> and <i>In Vivo</i> Investigation of S1PR1 Expression in the Central Nervous System Using [³ H]CS1P1 and [¹¹ C]CS1P1. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3733-3744.	1.7	13
33	Neuropathology of blepharospasm. <i>Experimental Neurology</i> , 2021, 346, 113855.	2.0	7
34	Dopamine D1&D3 receptor density may correlate with parkinson disease clinical features. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 224-237.	1.7	12
35	PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to <i>S. aureus</i> Infection. <i>Molecular Imaging</i> , 2021, 2021, 9982020.	0.7	5
36	In vitro characterization of [3H]VAT in cells, animal and human brain tissues for vesicular acetylcholine transporter. <i>European Journal of Pharmacology</i> , 2021, 911, 174556.	1.7	2

#	ARTICLE	IF	CITATIONS
37	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2020, 152, 235-251.	2.1	17
38	Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD). <i>Quality of Life Research</i> , 2020, 29, 1393-1403.	1.5	8
39	Proteinopathy and longitudinal changes in functional connectivity networks in Parkinson disease. <i>Neurology</i> , 2020, 94, e718-e728.	1.5	26
40	Cognitive correlates of cerebellar resting-state functional connectivity in Parkinson disease. <i>Neurology</i> , 2020, 94, e384-e396.	1.5	30
41	The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VACHT in the brain of nonhuman primates. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105152.	1.9	4
42	Little Change in Functional Brain Networks Following Acute Levodopa in Drug-naïve Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 499-503.	2.2	12
43	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. <i>Ageing Research Reviews</i> , 2020, 57, 100994.	5.0	57
44	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 196.	2.4	8
45	Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8860.	1.8	3
46	A Clinical Trial of Isradipine: What Went Wrong?. <i>Annals of Internal Medicine</i> , 2020, 172, 625-626.	2.0	13
47	Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112713.	2.6	8
48	Regional, not global, functional connectivity contributes to isolated focal dystonia. <i>Neurology</i> , 2020, 95, e2246-e2258.	1.5	23
49	Clinical and Demographic Characteristics of Upper Limb Dystonia. <i>Movement Disorders</i> , 2020, 35, 2086-2090.	2.2	9
50	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6047.	1.8	8
51	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). <i>Quality of Life Research</i> , 2020, 29, 3419-3439.	1.5	9
52	Defining research priorities in dystonia. <i>Neurology</i> , 2020, 94, 526-537.	1.5	26
53	Parkinson disease clinical subtypes: key features & clinical milestones. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1272-1283.	1.7	27
54	Removal of high frequency contamination from motion estimates in single-band fMRI saves data without biasing functional connectivity. <i>NeuroImage</i> , 2020, 217, 116866.	2.1	62

#	ARTICLE	IF	CITATIONS
55	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	5.8	102
56	Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study. Operative Neurosurgery, 2020, 19, 234-240.	0.4	2
57	It's tricky: Rating alleviating maneuvers in cervical dystonia. Journal of the Neurological Sciences, 2020, 419, 117205.	0.3	6
58	Postural Directionality and Head Tremor in Cervical Dystonia. Tremor and Other Hyperkinetic Movements, 2020, 10, .	1.1	10
59	Emergent Functional Network Effects in Parkinson Disease. Cerebral Cortex, 2019, 29, 2509-2523.	1.6	56
60	Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [¹¹ C]CS1P1 for human use. Applied Radiation and Isotopes, 2019, 152, 30-36.	0.7	6
61	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. Parkinson's Disease, 2019, 2019, 1-12.	0.6	23
62	Striatal DAT SPECT: Caveat Emptor!. Movement Disorders, 2019, 34, 1430-1432.	2.2	6
63	Detecting associations between intact connectomes and clinical covariates using recursive partitioning object-oriented data analysis. Statistics in Medicine, 2019, 38, 5486-5496.	0.8	1
64	How different aspects of motor dysfunction influence day-to-day function in huntington's disease. Movement Disorders, 2019, 34, 1910-1914.	2.2	3
65	Head tremor at disease onset: an ataxic phenotype of cervical dystonia. Journal of Neurology, 2019, 266, 1844-1851.	1.8	30
66	Thalamic and ventricular volumes predict motor response to deep brain stimulation for Parkinson's disease. Parkinsonism and Related Disorders, 2019, 61, 64-69.	1.1	18
67	Quantitative, clinically relevant acoustic measurements of focal embouchure dystonia. Movement Disorders, 2018, 33, 449-458.	2.2	12
68	Synthesis and in vitro characterization of a P2X7 radioligand [¹²³ I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease. European Journal of Pharmacology, 2018, 820, 8-17.	1.7	37
69	Kinetic modeling of [¹⁸ F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain. Journal of Neurochemistry, 2018, 144, 791-804.	2.1	21
70	Cervical dystonia and substance abuse. Journal of Neurology, 2018, 265, 970-975.	1.8	17
71	Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid- ¹⁴ C in Mice and Primates. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 543-554.	0.6	9
72	[¹⁸ F]FDOPA positron emission tomography in manganese-exposed workers. NeuroToxicology, 2018, 64, 43-49.	1.4	23

#	ARTICLE	IF	CITATIONS
73	Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?. <i>Toxicon</i> , 2018, 147, 89-95.	0.8	46
74	Syntheses and <i>in vitro</i> biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 9171-9184.	1.5	7
75	Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3425-3430.	1.0	2
76	Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques. <i>PLoS ONE</i> , 2018, 13, e0202201.	1.1	15
77	ESM-CT: a precise method for localization of DBS electrodes in CT images. <i>Journal of Neuroscience Methods</i> , 2018, 308, 366-376.	1.3	6
78	Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 657.	1.2	47
79	Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease. <i>Journal of Huntington's Disease</i> , 2018, 7, 239-249.	0.9	18
80	Selective D2 receptor PET in manganese-exposed workers. <i>Neurology</i> , 2018, 91, e1022-e1030.	1.5	27
81	Mapping movement, mood, motivation and mentation in the subthalamic nucleus. <i>Royal Society Open Science</i> , 2018, 5, 171177.	1.1	29
82	Exploration of Sulfur-Containing Analogues for Imaging Vesicular Acetylcholine Transporter in the Brain. <i>ChemMedChem</i> , 2018, 13, 1978-1987.	1.6	3
83	PET Imaging in Movement Disorders. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 513-524.	2.5	13
84	Striatal molecular imaging of presynaptic markers. <i>Neurology</i> , 2017, 88, 1388-1389.	1.5	0
85	Chiral resolution of serial potent and selective β_1 ligands and biological evaluation of (β)-[18 F] TZ3108 in rodent and the nonhuman primate brain. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1533-1542.	1.4	4
86	ACR Appropriateness Criteria $\text{\textcircled{R}}$ Cerebrovascular Disease. <i>Journal of the American College of Radiology</i> , 2017, 14, S34-S61.	0.9	71
87	Psychiatric associations of adult-onset focal dystonia phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 595-602.	0.9	76
88	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017, 88, 152-159.	1.5	104
89	Adult-onset dystonia with marfanoid features. <i>Neurology: Clinical Practice</i> , 2017, 7, e31-e34.	0.8	1
90	Synthesis, resolution, and <i>in vitro</i> evaluation of three vesicular acetylcholine transporter ligands and evaluation of the lead fluorine-18 radioligand in a nonhuman primate. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 5197-5209.	1.5	7

#	ARTICLE	IF	CITATIONS
91	TMEM230 in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 212.e1-212.e3.	1.5	9
92	Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. <i>Journal of Psychiatric Research</i> , 2017, 86, 9-17.	1.5	17
93	ACR Appropriateness Criteria Â® Cranial Neuropathy. <i>Journal of the American College of Radiology</i> , 2017, 14, S406-S420.	0.9	10
94	Sex-specific effects of the Huntington gene on normal neurodevelopment. <i>Journal of Neuroscience Research</i> , 2017, 95, 398-408.	1.3	41
95	Research Priorities in Limb and Task-Specific Dystonias. <i>Frontiers in Neurology</i> , 2017, 8, 170.	1.1	34
96	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. <i>BMC Neurology</i> , 2017, 17, 198.	0.8	55
97	Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. <i>Synapse</i> , 2016, 70, 418-431.	0.6	44
98	Clinical and genetic features of cervical dystonia in a large multicenter cohort. <i>Neurology: Genetics</i> , 2016, 2, e69.	0.9	44
99	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016, 31, 563-569.	2.2	36
100	ACR Appropriateness Criteria Low Back Pain. <i>Journal of the American College of Radiology</i> , 2016, 13, 1069-1078.	0.9	147
101	Objective, computerized video-based rating of blepharospasm severity. <i>Neurology</i> , 2016, 87, 2146-2153.	1.5	20
102	Clinical and demographic characteristics related to onset site and spread of cervical dystonia. <i>Movement Disorders</i> , 2016, 31, 1874-1882.	2.2	39
103	Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAcHt in nonhuman primates. <i>Nuclear Medicine and Biology</i> , 2016, 43, 131-139.	0.3	13
104	Automated production of [18 F]VAT suitable for clinical PET study of vesicular acetylcholine transporter. <i>Applied Radiation and Isotopes</i> , 2016, 107, 40-46.	0.7	15
105	Absorbed radiation dosimetry of the D-specific PET radioligand [F]FluorTriopride estimated using rodent and nonhuman primate. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 301-309.	1.0	6
106	Emotional Eating Phenotype is Associated with Central Dopamine D2 Receptor Binding Independent of Body Mass Index. <i>Scientific Reports</i> , 2015, 5, 11283.	1.6	38
107	Radiation dosimetry of [18F]VAT in nonhuman primates. <i>EJNMMI Research</i> , 2015, 5, 73.	1.1	12
108	Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. <i>PLoS ONE</i> , 2015, 10, e0133621.	1.1	50

#	ARTICLE	IF	CITATIONS
109	Cognitive reserve and β -amyloid pathology in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 899-904.	1.1	34
110	Synthesis and biological characterization of a promising F-18 PET tracer for vesicular acetylcholine transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4699-4709.	1.4	34
111	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 949-959.	1.7	144
112	ACR Appropriateness Criteria Dementia and Movement Disorders. <i>Journal of the American College of Radiology</i> , 2015, 12, 19-28.	0.9	14
113	Levodopa-responsive Hemiparkinsonism Secondary to Cystic Expansion from a Coiled Cerebral Aneurysm. <i>Journal of Neuroimaging</i> , 2015, 25, 316-318.	1.0	2
114	Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject. <i>NeuroImage</i> , 2015, 121, 253-262.	2.1	16
115	CSF proteins and resting-state functional connectivity in Parkinson disease. <i>Neurology</i> , 2015, 84, 2413-2421.	1.5	51
116	In vitro and ex vivo characterization of (α)-TZ659 as a ligand for imaging the vesicular acetylcholine transporter. <i>European Journal of Pharmacology</i> , 2015, 752, 18-25.	1.7	6
117	Secured web-based video repository for multicenter studies. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 366-371.	1.1	21
118	Comparing interventions and exploring neural mechanisms of exercise in Parkinson disease: a study protocol for a randomized controlled trial. <i>BMC Neurology</i> , 2015, 15, 9.	0.8	31
119	Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 135-141.	0.8	47
120	Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8584-8600.	2.9	25
121	Correlation between decreased CSF β -synuclein and α -synuclein in Parkinson disease. <i>Neurobiology of Aging</i> , 2015, 36, 476-484.	1.5	59
122	Additive global cerebral blood flow normalization in arterial spin labeling perfusion imaging. <i>PeerJ</i> , 2015, 3, e834.	0.9	5
123	The role of dopamine and dopaminergic pathways in dystonia: insights from neuroimaging. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 280.	1.1	11
124	Comment: fMRI biomarker for premanifest HD?. <i>Neurology</i> , 2014, 83, 71-71.	1.5	0
125	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
126	Radiosynthesis and in vivo evaluation of a novel β 1 selective PET ligand. <i>MedChemComm</i> , 2014, 5, 1669-1677.	3.5	3

#	ARTICLE	IF	CITATIONS
127	Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2648-2654.	1.4	19
128	Acute Changes in Mood Induced by Subthalamic Deep Brain Stimulation in Parkinson Disease Are Modulated by Psychiatric Diagnosis. <i>Brain Stimulation</i> , 2014, 7, 701-708.	0.7	21
129	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	9.4	1,685
130	Syntheses and Radiosyntheses of Two Carbon-11 Labeled Potent and Selective Radioligands for Imaging Vesicular Acetylcholine Transporter. <i>Molecular Imaging and Biology</i> , 2014, 16, 765-772.	1.3	8
131	In Vitro and In Vivo Characterization of Two C-11-Labeled PET Tracers for Vesicular Acetylcholine Transporter. <i>Molecular Imaging and Biology</i> , 2014, 16, 773-780.	1.3	10
132	Brain activity during complex imagined gait tasks in Parkinson disease. <i>Clinical Neurophysiology</i> , 2014, 125, 995-1005.	0.7	57
133	Visuomotor adaptation in Parkinson's disease: effects of perturbation type and medication state. <i>Journal of Neurophysiology</i> , 2014, 111, 2675-2687.	0.9	14
134	Spatial Reorganization of Putaminal Dopamine D2-Like Receptors in Cranial and Hand Dystonia. <i>PLoS ONE</i> , 2014, 9, e88121.	1.1	17
135	Gait-Related Brain Activity in People with Parkinson Disease with Freezing of Gait. <i>PLoS ONE</i> , 2014, 9, e90634.	1.1	88
136	Heteroaromatic and Aniline Derivatives of Piperidines As Potent Ligands for Vesicular Acetylcholine Transporter. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6216-6233.	2.9	24
137	Pathologic Accumulation of α -Synuclein and $A\beta$ in Parkinson Disease Patients With Dementia. <i>Archives of Neurology</i> , 2012, 69, 1326.	4.9	173
138	Amyloid imaging of Lewy body-associated disorders. <i>Movement Disorders</i> , 2010, 25, 2516-2523.	2.2	135
139	DEEP BRAIN STIMULATION. <i>Annual Review of Neuroscience</i> , 2006, 29, 229-257.	5.0	820
140	[¹⁸ F]FDOPA PET and clinical features in parkinsonism due to manganism. <i>Movement Disorders</i> , 2005, 20, 492-496.	2.2	106
141	Dysfunction of dopaminergic pathways in dystonia. <i>Advances in Neurology</i> , 2004, 94, 163-70.	0.8	65
142	Late-Onset neurodegeneration with brain iron accumulation type 1: Expanding the clinical spectrum. <i>Movement Disorders</i> , 2001, 16, 1148-1152.	2.2	18
143	Chorea and jaw-opening dystonia as a manifestation of Neurobehcet's syndrome. <i>Movement Disorders</i> , 2000, 15, 741-744.	2.2	18
144	Dopamine D ₁ Agonist Activates Temporal Lobe Structures in Primates. <i>Journal of Neurophysiology</i> , 2000, 84, 549-557.	0.9	23

#	ARTICLE	IF	CITATIONS
145	Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa. <i>Strabismus</i> , 1999, 7, 169-174.	0.4	62
146	Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. , 1999, 88, 539-543.		99
147	Mutational and biochemical analysis of dopamine in dystonia. <i>Molecular Neurobiology</i> , 1998, 16, 135-147.	1.9	42
148	Decreased [¹⁸ F]Spiperone Binding in Putamen in Idiopathic Focal Dystonia. <i>Journal of Neuroscience</i> , 1997, 17, 843-850.	1.7	225
149	Vibration-Induced Regional Cerebral Blood Flow Responses in Normal Aging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1992, 12, 554-561.	2.4	27
150	Regional Correction of Positron Emission Tomography Data for the Effects of Cerebral Atrophy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1988, 8, 662-670.	2.4	85
151	Brain Blood Volume, Flow, and Oxygen Utilization Measured with ¹⁵ O Radiotracers and Positron Emission Tomography: Revised Metabolic Computations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, 513-516.	2.4	85
152	V. Anatomical Considerations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, S16-S18.	2.4	9
153	In vitro or in vivo receptor binding: Where does the truth lie?. <i>Annals of Neurology</i> , 1986, 19, 384-385.	2.8	24
154	Parkinson's disease: Metabolic and pharmacological approaches with positron emission tomography. <i>Annals of Neurology</i> , 1984, 15, 131-132.	2.8	13